Walk through the departure hall at Incheon Airport and you will pass it within ninety seconds. A glossy red box, gold lettering, a price tag somewhere between 80,000 and 600,000 won. Inside sits a paste the color of dark honey, made from a root that spent six years underground before anyone dug it up. For roughly forty years, that box was the default Korean souvenir — the thing you brought back for a boss, a mother-in-law, a business partner in Shanghai. Yet the Korea ginseng industry that fills those boxes is now shrinking faster than almost any other food category in the country.
The numbers are blunt. Ginseng exports peaked at $269 million in 2022. By 2025 they had fallen to $203.2 million, an 18.4 percent drop in a single year. Then came 2026, and the floor gave way again: in the first half alone, ginseng shipments fell 33.2 percent to just $61.7 million.
Here is what makes that strange. Korean food exports are having the best run in their history. K-Food+ shipments hit a record $7.05 billion in the first half of 2026, up 4.1 percent, with ramen alone pulling in $935 million. Ramen is up 27.9 percent. Frozen strawberries are up 15.9 percent. Meanwhile the original K-food — the one that had global brand recognition decades before Parasite, before BTS, before the tteokbokki aisle at your local supermarket — is going backwards.
So what happened to insam?
First, a quick primer for anyone who has only met ginseng as a word on a label. Insam is the Korean name for Panax ginseng, a slow-growing root cultivated under low black shade nets across the country’s hillsides. Korea has been farming it for roughly 1,500 years. Moreover, the root carries a cultural weight abroad that few other Korean products match: in Chinese-speaking markets, “Goryeo insam” has functioned as a luxury signal for centuries, rather like Bordeaux or Swiss watches. Because of that history, ginseng was Korea’s original soft-power export — long before anyone coined the phrase K-food.
Three years down: the Korea ginseng industry in numbers
Let us start with the export curve, because it tells the cleanest story.
In 2022, Korean ginseng exports reached an all-time high of about $269 million. Two years later they had slipped to $249 million. In 2025, they collapsed to $203.2 million. That is a fall of roughly a quarter from the peak, and it happened while nearly every other Korean agricultural export was climbing.
The first half of 2026 was worse. Shipments of $61.7 million represented a 33.2 percent year-on-year decline — steeper than any single-year drop in the previous decade. If the second half matches, annual exports will land somewhere near $130 million, which would put the sector back where it stood in the early 2010s.
Ginseng exports do not fail for one reason. Instead, four separate pressures arrived at roughly the same time. First, a regulatory wall went up in China. Second, a generational shift changed how people buy supplements. Third, the farm economy stopped making sense. Finally, a Chinese domestic industry grew large enough to compete outright. Each of those deserves its own look.
The China problem: when a root becomes a drug
Greater China — mainland China, Hong Kong and Taiwan — has always been the load-bearing wall of the Korea ginseng industry. Consequently, anything Beijing does to the rules lands directly on Korean farmers and processors.
Beijing has been busy. China is revising its import standard for Korean red ginseng as a medicinal material. The practical effect is severe. Roots aged six years or more get classified as pharmaceutical products rather than food. That distinction sounds bureaucratic. In reality, it changes everything about how a product is imported, labelled, priced and sold.
Six-year roots are the crown jewels of Korean cultivation. Furthermore, the entire premium tier rests on them. Jung Kwan Jang uses six-year roots exclusively, and Korean marketing has spent decades teaching Asian consumers that six years means quality. Reclassifying that exact segment as medicine locks the highest-margin product out of ordinary retail.
Buyers did not stop buying entirely. Rather, they shifted down the value chain, toward concentrates, extracts and processed goods that clear customs as food. Volume held up better than value as a result. Margins did not. Korean exporters found themselves shipping more boxes for less money — the classic signature of a market losing pricing power.
Vietnam added its own complication by revising its food safety law, tightening the registration requirements that health products must satisfy. Additionally, domestic production costs in Korea have risen sharply, so Korean ginseng is arriving in these markets more expensive at precisely the moment the paperwork got harder. Trade officials have a polite term for all of this: non-tariff barriers. Exporters have a less polite one.
What replaced it: the vitamin shelf won
The second pressure is not about trade policy at all. Instead, it is about what a 28-year-old in Seoul, Taipei or Shanghai actually puts in their cart.
Korean red ginseng used to own the domestic health-supplement market outright. In 2021, households spent 1.47 trillion won on it, and it commanded 25.9 percent of all health functional food purchases. By 2025, spending had fallen to 953.6 billion won — roughly 500 billion won evaporated in four years — and its market share had dropped to 16 percent.
Where did the money go? Largely to vitamins. Multivitamin and mineral purchases climbed from 13.6 percent of the market in 2021 to 18.1 percent in 2025, crossing the one-trillion-won line. Probiotics grew too. So did a long tail of single-ingredient products: magnesium, coenzyme Q10, dietary fibre, lutein. That “other” category expanded from 22.3 percent to 32.8 percent, which is the clearest possible sign of a market fragmenting.
The generational split is stark. Among Koreans aged 21 to 30, red ginseng ranks fourth at 8.2 percent, well behind body-fat reduction products, probiotics and multivitamins. For the 31-to-40 bracket, it slips to fifth at 6.4 percent. Only among people over 51 does ginseng still finish first.
A second, quieter force is also at work: the gift economy is shrinking. Red ginseng sets were never bought mainly for personal use. Instead, they moved during Seollal and Chuseok, between companies, in-laws and clients. Yet that ritual is thinning. Korea’s anti-graft law caps the value of agricultural gifts to public officials, teachers and journalists. Corporate holiday budgets have tightened too. Furthermore, single-person households now make up more than a third of all Korean households, and a household of one sends fewer obligatory boxes.
Younger consumers describe the rest of the problem in almost identical language: expensive, and old. A 300,000-won gift box built around Confucian filial duty does not compete well against a 20,000-won bottle of gummies. Meanwhile, other wellness categories in Korea are booming. Consider protein and zero-sugar “healthy pleasure” products, or the sprawling functional food sector now worth over $10 billion. Those categories win because they feel casual, cheap and individually chosen.
Ginseng, by contrast, still markets itself as an obligation.
Inside Jung Kwan Jang: the weight of 126 years
You cannot discuss the Korea ginseng industry without discussing one company, because for practical purposes the two are the same thing.
Jung Kwan Jang is the flagship brand of KGC, the Korea Ginseng Corporation. Its lineage runs back to 1899, when the Korean Empire set up a ginseng administration office under the royal household. Red ginseng then stayed a state monopoly for most of the following century. Indeed, that monopoly was not fully abolished until 2011. Korea’s most famous health brand therefore spent 112 years as, essentially, a government department. Today it sits inside KT&G, the former state tobacco and ginseng company.
That history explains both the brand’s power and its stiffness. On one hand, Jung Kwan Jang sells in more than 40 countries and runs retail stores in eight. Moreover, it reinvests around 20 percent of annual profits into R&D, employs over 130 researchers, and has been ranked the world’s number-one ginseng brand by Euromonitor. On the other hand, it was built to defend a monopoly. Fighting a Californian gummy startup for shelf space is a different sport.
The 2025 results show the squeeze. Revenue fell 12.6 percent to 1.138 trillion won. Operating profit, however, edged up 4.7 percent to 102.8 billion won. That was the first profitability rebound in five years. Notably, it came from cutting costs and pushing high-margin lines through duty-free and online channels, not from selling more product. The fourth quarter was rougher still: sales dropped 24.8 percent year-on-year.
Managing profit while revenue shrinks is a legitimate strategy. Still, it is the strategy of a company defending a position rather than expanding one. The duty-free channel it leans on also has its own problems. After all, Korea’s duty-free empire has been contracting hard since the Chinese group-tour era ended.
The farm math: why the Korea ginseng industry is losing growers
Now for the part of the story that no marketing budget can fix.
Insam is one of the most punishing crops in Korean agriculture. A six-year root requires six years of shade structures, drainage management and disease control before it earns a single won. Worse, the land cannot simply be replanted afterwards. Ginseng exhausts soil so thoroughly that a field typically needs a decade before it can carry the crop again. Farmers therefore have to keep leasing new plots, forever.
Predictably, they are quitting.
The 2024 figures are brutal across every measure. Production fell 18.7 percent in one year, from 22,471 tonnes to 18,272 tonnes. Cultivated area shrank 9.9 percent to 10,585 hectares. Harvested area dropped 14.5 percent. Farm households growing ginseng fell 10.1 percent, from 17,662 to 15,877.
The forward-looking numbers are worse than the current ones. Newly planted area has fallen 68.3 percent since 2008, from 5,263 hectares to 1,667. New households entering the Korea ginseng industry dropped from 5,848 in 2020 to 2,294 in 2024. That is a 60.8 percent collapse in four years. Because insam takes six years to mature, today’s planting decisions set the supply curve for 2032. On current trends, that curve points down.
Climate change is accelerating the exit. Ginseng hates heat; above roughly 30°C it stops growing and becomes vulnerable to rot. Consequently, cultivation keeps migrating northward and upward. Growers have moved out of traditional heartlands such as Geumsan and into the mountains of Gangwon, and even into Cheorwon near the DMZ. Each move raises costs.
Scarcity is now showing up at the counter. The price of 750g of fresh ginseng jumped 41.2 percent in a single year, from 23,326 won to 32,931 won. Higher farmgate prices sound good for growers. However, they are catastrophic for exporters already told they are too expensive. That is how an industry ends up with rising input costs and falling foreign demand at once. Korean agriculture has seen this pattern before, most recently when cheap Chinese kimchi took over restaurant tables.
Does Korean red ginseng actually work?
Foreign readers ask this constantly, so it deserves a straight answer rather than a marketing one.
The evidence is real but modest. According to the US National Center for Complementary and Integrative Health, Asian ginseng shows some benefit for cognitive measures in middle-aged adults, including attention and reaction time. A 2023 review found a small positive effect on general fatigue. Moreover, a 2022 analysis reported improvements in cardiometabolic markers such as fasting glucose among people with prediabetes and diabetes. There is limited evidence for erectile dysfunction as well.
Elsewhere the picture thins out quickly. Most studies find no benefit for athletic performance. Evidence for flu prevention, asthma, anxiety and anti-ageing remains insufficient. Long-term safety data is thin, insomnia is a common side effect, and ginseng can interact with medications and lower blood sugar. Pregnant and breastfeeding women are advised to avoid it.
In short: ginsenosides are not snake oil, but they are also not the miracle the gift box implies. That gap matters commercially. Younger consumers research supplements before buying, and a product sold on tradition rather than clinical claims is unusually exposed when the shopper opens a browser tab.
Jilin’s shadow: China is building its own insam
Meanwhile, a competitor to the Korea ginseng industry has been quietly scaling just across the northern border.
China’s ginseng industry is centred on Jilin province, along the Changbai Mountain range that Koreans call Baekdu. The region harvested about 34,000 tonnes in 2023 — nearly double Korea’s entire national output. Fusong county alone hosts what Chinese officials describe as the world’s largest ginseng market, handling around 80 percent of China’s ginseng trade. In 2023, Jilin’s ginseng industry reported comprehensive output value of 70 billion yuan, or roughly $9.94 billion, up 10.3 percent year-on-year.
Compare that with Korean ginseng exports of $203 million and the asymmetry becomes obvious. Jilin is not merely growing roots anymore, either; the province is running a Changbai Mountain Ginseng Revitalization Project aimed at quality, branding and higher-value processing. That is precisely the ladder Korean firms climbed in the 1990s.
Seen in this light, China’s regulatory tightening looks less like an accident of paperwork and more like industrial policy. Whether or not that reading is fair, the outcome for Korean exporters is identical.
Where the Korea ginseng industry goes next
Nobody in Seoul is treating this as terminal. Rather, the response is splitting along three tracks.
The first is geographic. Korea’s agricultural trade agency, aT, is pushing into Europe and the Middle East with trade fairs and K-Food events. More importantly, it is helping exporters register health products under local regulatory regimes. That last piece matters far more than the promotional spending, because registration is where most Korean supplement exports die. Early signs are mildly encouraging. Middle East shipments of K-Food+ rose 25.2 percent in the first half of 2026, and ginseng was among the recovering items there.
The second track is product. Concentrates, sticks, jellies, tablets and ready-to-drink shots now do the work that sliced roots and gift sets once did. Additionally, KGC has been building region-specific portfolios instead of exporting the Korean lineup wholesale. The company also says it will lean harder on scientific efficacy claims abroad. That is an implicit admission that heritage alone no longer sells.
The third track is cultural. Korea has submitted a nomination to UNESCO in Paris seeking recognition of Korean ginseng culture as Intangible Cultural Heritage. Meanwhile, the traditional growing regions of Geumsan, Ganghwa and Punggi are assembling the documentation. Cultural designation will not fix an export curve by itself. Nevertheless, it does something the industry badly needs. It reframes insam as heritage worth experiencing rather than a supplement worth comparing on price. Korea has run that playbook before, and the country’s inbound tourism boom is the obvious channel for it.
There is one more possibility that the industry rarely says out loud. Korea is ageing faster than any other developed nation, and the silver economy is already a $128 billion market. Korean red ginseng still ranks first among consumers over 51. So a brand that spent 126 years selling to older Koreans may find its core customer base becoming the largest demographic in the country.
A buyer’s guide to Korean red ginseng
If you are visiting Korea and want to buy intelligently rather than by box size, a few practical points help.
Understand the tiers. Susam is fresh ginseng. Baeksam (white ginseng) is peeled and dried. Hongsam (red ginseng) is steamed and dried, which is the processing step that creates the compounds most of the research focuses on. Price rises sharply along that sequence.
Six years is the premium claim, not a legal guarantee of effect. Six-year roots command the highest prices and anchor the top brands. Still, four- and five-year products cost far less and are not nutritionally worthless.
Format matters more than romance. Whole roots in a display case photograph beautifully. However, extracts, sticks and pouches are far easier to actually consume daily, and daily consumption is what any of the evidence assumes.
Where to buy. Duty-free stores carry the widest premium selection and frequent promotions. Jung Kwan Jang also runs standalone shops nationwide. For atmosphere, though, the ginseng markets in Geumsan are the real thing. The Geumsan World K-Insam Festival runs 2–11 October 2026, with digging experiences, red ginseng foot baths and an international trade fair. Admission is free.
Check with a doctor if you take medication. Ginseng can lower blood sugar and interacts with several drug classes. That caveat applies whatever the gift box says.
The bigger lesson
The Korea ginseng industry is not collapsing because the product got worse. Rather, it is struggling because it was built for a world that no longer exists. That world ran on state monopolies, Chinese group tours, formal gift-giving obligations and one dominant brand that never had to fight for attention.
Everything about Korean food exports today runs the opposite way. Ramen wins because it is cheap, casual and meme-friendly. Skincare wins because it is unbundled and specific. Ginseng, so far, has not made that translation.
The raw material is still there. Korea has 1,500 years of cultivation knowledge, genuine clinical literature, a brand recognised across Asia, and a UNESCO bid in progress. Rebuilding around all that will take something harder than a marketing refresh. Ultimately, it means persuading a 28-year-old in Berlin or Riyadh that a six-year-old root is worth the money — without the deference that used to make the sale automatic.
The next planting season starts soon. Whatever gets put in the ground this autumn will not be harvested until 2032.
